Biogen (BIIB) Long-Term Investments (2009 - 2026)

Biogen's Long-Term Investments history runs 17 years deep, the most recent figure standing at $465.6 million for Q1 2026.

• In Q1 2026, Long-Term Investments changed N/A year-over-year to $465.6 million; the TTM figure through Mar 2026 stood at $465.6 million (changed N/A YoY), while the FY2025 annual figure was $431.9 million, changed N/A from the prior year.
• Long-Term Investments for Q1 2026 stood at $465.6 million, up from $431.9 million in the prior quarter.
• The five-year high for Long-Term Investments was $1.2 billion in Q2 2023, with the low at $100000.0 in Q3 2023.
• The 4-year median for Long-Term Investments is $860.3 million (2022), against an average of $750.5 million.
• The sharpest annual moves came in 2022 and 2023: Long-Term Investments rose 21.86% in 2022, then tumbled 99.99% in 2023.
• Biogen's Long-Term Investments stood at $705.7 million in 2022, then tumbled by 99.99% to $100000.0 in 2023, then soared by 431800.0% to $431.9 million in 2025, then climbed by 7.8% to $465.6 million in 2026.
• Business Quant data shows BIIB's Long-Term Investments at $465.6 million in Q1 2026, $431.9 million in Q4 2025, and $100000.0 in Q3 2023.